Even after treatment with checkpoint blockade immunotherapies (CBI), including antibodies for cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed-cell-death protein 1 (PD-1), most patients presented insufficient systemic immune responses for tumor regression13–15. Here, PDCD1 is linked to neoplasm.